Hyloris Pharmaceuticals (LTS:0AB6) Dividends per Share : €0.00 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Dividends per Share?

Hyloris Pharmaceuticals's dividends per share for the six months ended in Dec. 2023 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Hyloris Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Hyloris Pharmaceuticals Dividends per Share Historical Data

The historical data trend for Hyloris Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Dividends per Share Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Hyloris Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Dividend Yield % falls into.

Hyloris Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Hyloris Pharmaceuticals (LTS:0AB6) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Hyloris Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.326
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Hyloris Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines